Bio|Path Holdings Inc. filed SEC Form 8|K
FORM 10-K THE CHARLES SCHWAB CORPORATION
Title of each class. Trading Symbol(s). Name of each exchange on which registered. Common Stock – $.01 par value per share.
SEC Documents | BioCryst Pharmaceuticals, Inc.
Nov 07, 2024. An amendment to the SC 13G filing. SC 13G/A ; Nov 05, 2024. Quarterly report which provides a continuing view of a company's financial position. 10 ...
Form 8-K for Gossamer BIO INC filed 03/12/2024
Drynan worked for Capital Group, where she was a Partner and a Senior BioPharma Analyst. Prior to joining Capital Group, she served as a ...
SEC Filing - Investor Relations - Leidos
LEIDOS HOLDINGS, INC. (Exact name of registrant as specified in ... Check the appropriate box below if the Form 8-K filing is intended ...
Biopath Holdings Inc (BPTH) 8-K Listing Status - Mar 2024 - Last10K
Search for companies. Biopath Holdings Inc (BPTH) SEC Filing 8-K Material Event for the period ending Tuesday, March 12, 2024.
Lantheus Reports Third Quarter 2024 Financial Results
SEC Filings · Supplemental Financial ... Form 10-K and our Quarterly Reports on Form 10-Q). - Tables Follow -. Lantheus Holdings, Inc.
SEC Filings | Verde Bio Holdings
8-K, Current report pursuant to Section 13 or 15(d), 2, 2024-03-26. 10-Q, General ... Verde Bio Holdings, Inc. 5750 Genesis Court, Suite 220B Frisco, TX ...
Sirius XM Holdings Inc. (SIRI)
SiriusXM is the leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment ...
UPDATE - Tevogen Founder Reflects on Importance of Preserving ...
14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc. ... Form 10-K and subsequent filings with the SEC. You should ...
Ginkgo Bioworks: Investor Relations
Headquartered in Boston, Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers.
BIO-PATH HOLDINGS INC Form 10-Q Quarterly Report Filed 2020 ...
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities.
0001367644-08-000016 | 10-K/A | Emergent BioSolutions Inc.
SEC Filing Details. Document Details. Form. 10-K/A. Filing Date. Mar 13, 2008 ... Filing Group. Annual Filings. Company. Emergent BioSolutions Inc. Issuer.
Investor Updates - Alphabet Investor Relations
10-K. PDF · HTML · More Earnings. News. October 29, 2024. Alphabet Announces Third ... All SEC Filings. Quarterly and Annual Reports. Proxy Filings. Section 16 ...
0001171843-23-004029 | 8-K - Arbutus Biopharma Corporation
SEC Filing Details. Document Details. Form. 8-K. Filing Date. Jun 21, 2023. Document Date. Jun 21, 2023. Form Description. Report of unscheduled material events ...
Form 8-K for Bionano Genomics INC filed 09/09/2024
On September 4, 2024, Bionano Genomics, Inc. (the “Company”) committed to a reorganization plan (the “Plan”), including a reduction in force ...
SEC Filings - bluebird bio, Inc.
Filing Group, View. 02/13/24, SC 13G/A. An amendment to the SC 13G filing ... Amendment to a previously filed 8-K. Current Reports. View HTML · 0001564590-16 ...
Supplemental Prospectus - Form 424B3 - Public now
The accompanying notes to condensed consolidated financial statements are an integral part of these statements. 3. Panbela Therapeutics, Inc.
(8) The term "unfair labor practice" means any unfair labor practice listed in section 8 [section 158 of this title]. ... filed charges or given testimony under ...
0001370053-20-000042 | 8-K - AnaptysBio, Inc.
SEC Filing Details. SEC Filing Details. Document Details. Form. 8-K ... Filing Group. Current Reports. Company. AnaptysBio, Inc. Issuer.
SEC Filing - Investors - Kala Bio
KALA BIO, Inc. (Name of Issuer). Common Stock, par value $0.001 per share. (Title of Class of Securities). 483119202. (CUSIP number).